Impact of mutation on aggressiveness and outcomes in adult clonal histiocytosis.
Fiche publication
Date publication
septembre 2023
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
Tous les auteurs :
Razanamahery J, Godot A, Leguy-Seguin V, Samson M, Audia S, Bonnotte B
Lien Pubmed
Résumé
Histiocytoses encompass a wide spectrum of diseases, all characterized by tissue infiltration by CD68+ histiocytes. Most adult histiocytoses are considered clonal diseases because they highlight recurrent somatic mutations in the MAP-kinase pathway gene, primarily . The presence of mutation is associated with widespread disease in children with Langerhans cell histiocytosis (LCH) or cardiovascular/neurological involvement in Erdheim-Chester disease (ECD). Nevertheless, few data are available on adult clonal histiocytosis. This is why we have conducted a retrospective study of all patients with clonal histiocytosis in our institution and present the data according to the presence of mutation. Among 27 adult patients (10 ECD, 10 LCH, 5 Rosai-Dorfman disease (RDD), and 3 mixed ECD/LCH), 11 (39%) have mutation with gain of function (n = 9) and deletion (n = 2). Those patients had frequent multicentric disease with risk organ involvement, especially the brain and cardiovascular system. They had frequent associated myeloid neoplasms (mostly chronic myelomonocytic leukemia) and received more frequently targeted therapy as the front-line therapy. Nevertheless, its presence did not affect the overall survival or relapse-free survival probably due to the emergence of efficient therapies. To conclude, rapid and accurate molecular establishment in adult clonal histiocytoses is crucial because mutation correlates with multicentric disease with organ involvement and incomplete metabolic response.
Mots clés
BRAF, Erdheim-Chester disease, Langerhans cell histiocytosis (LCH), Rosai Dorfman disease, histiocytosis
Référence
Front Immunol. 2023 09 22;14:1260193